Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;5(3):223-8.

Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival

Hossam K Mahmoud  1 , Yasser El Nahas, Mohamad Abdel Moaty, Raafat Abdel Fattah, Mohamad El Emary, Wafaa El Metnawy
Affiliations

Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival

Hossam K Mahmoud et al. Int J Biomed Sci. 2009 Sep.

Abstract

Purpose: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML.

Methods: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period (FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR.

Results: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001).

Discussion: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance, CCyR, or suggesting IM dose modification.

Keywords: ABL kinase mutations; CML; cytogenetic responses; imatinib mesylate; molecular responses.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Two log reductions in Bcr-Abl/Abl mRNA ratio at 6 months predicts better PFS at 24 months of IM therapy.
Figure 2
Figure 2
Overall survival of the 95 patients in the study group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;319:990. - PubMed
    1. Sawyers CL. Chronic Myeloid Leukemia. N. Engl. J. Med. 1999;340:1330. - PubMed
    1. Druker BJ, Talpaz M, Resta DJ, Peng B, et al. Efficacy and safety of a specific inhibitor of bcr abl tyrosine kinase in chronic myeloid leukemia. N. England J. Med. 2001;344:1031. - PubMed
    1. Hochhaus A, Druker BJ, Larson RA, O'Brien SG, et al. IRIS 6-Year Follow up: Sustained survival and declining Annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2007;110(11) [abstract 25]
    1. Cortes J, Talpaz M, O'Brien S, Jones D, et al. Molecular responses in patients with chronic Myelogenous Leukemia in Chronic phase treated with Imatinib Mesylate. Clin. Cancer Res. 2005;11(9):3425. - PubMed

LinkOut - more resources